Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

Vertex Pharmaceuticals ( VRTX +0.01%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth ...

Vertex Pharmaceuticals is backed by CF dominance and JOURNAVX optionality, with key catalysts ahead for growth and upside.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The freshly linked pair is chasing new drugs to treat undisclosed autoimmune diseases and also to improve conditioning regimens for sickle cell disease and beta thalassemia. More gentle conditioning ...

ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of ...

The cystic fibrosis (CF) market in the seven major markets (7MM) is forecast to grow from $11.1 billion in 2024 to $16 ...

Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug ...

Vertex Pharmaceuticals (NASDAQ:VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...

Vertex Pharmaceuticals is partnering with California-based Enlaza Therapeutics in a deal aimed at advancing new conditioning ...

Enlaza Therapeutics partners with Vertex Pharmaceuticals to advance innovative therapies for autoimmune diseases using ...